Brexpiprazole

6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning, Warnings and Precautions ( 5.1 )] Suicidal Thoughts and Behaviors in Adolescents and Young Adults [see Boxed Warning, Warnings and Precautions ( 5.2 )] Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions ( 5.3 )] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions ( 5.4 )] Tardive Dyskinesia [see Warnings and Precautions ( 5.5 )] Metabolic Changes [see Warnings and Precautions ( 5.6 )] Pathological Gambling and Other Compulsive Behaviors [see Warnings and Precautions ( 5.7 )] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions ( 5.8 )] Orthostatic Hypotension and Syncope [see Warnings and Precautions ( 5.9 )] Falls [see Warnings and Precautions ( 5.10 )] Seizures [see Warnings and Precautions ( 5.11 )] Body Temperature Dysregulation [see Warnings and Precautions ( 5.12 )] Dysphagia [see Warnings and Precautions ( 5.13 )] Potential for Cognitive and Motor Impairment [see Warnings and Precautions ( 5.14 )] Most common adverse reactions in adults were ( 6.1 ): MDD: Weight increased and akathisia (greater than or equal to 5% and at least twice the rate for placebo) Schizophrenia: Weight increased (greater than or equal to 4% and at least twice the rate for placebo) To report SUSPECTED ADVERSE REACTIONS, contact Ajanta Pharma USA Inc. at 1-855-664-7744 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Major Depressive Disorder The safety of brexpiprazole tablets was evaluated in 1054 adult patients (18 to 65 years of age) diagnosed with MDD who participated in two 6-week placebo-controlled, fixed-dose clinical trials in patients with major depressive disorder in which brexpiprazole tablets was administered at doses of 1 mg to 3 mg daily as adjunctive treatment to continued antidepressant therapy; patients in the placebo group continued to receive antidepressant therapy [see Clinical Studies ( 14.1)]. Adverse Reactions Reported as Reasons for Discontinuation of Treatment A total of 3% (17/643) of brexpiprazole tablets-treated patients and 1% (3/411) of placebo-treated patients discontinued due to adverse reactions. Common Adverse Reactions Adverse reactions associated with the adjunctive use of brexpiprazole tablets (incidence of 2% or greater and adjunctive brexpiprazole tablets incidence greater than adjunctive placebo) that occurred during acute therapy (up to 6-weeks in patients with MDD) are shown in Table 7. Table 7: Adverse Reactions in Pooled 6-Week Placebo-Controlled, Fixed-Dose MDD Trials in Adults (Studies 1 and 2)* Placebo (N=411) Brexpiprazole Tablets 1 mg/day (N=226) 2 mg/day (N=188) 3 mg/day (N=229) All Brexpiprazole Tablets (N=643) Gastrointestinal Disorders Constipation 1% 3% 2% 1% 2% General Disorders and Administration Site Conditions Fatigue 2% 3% 2% 5% 3% Infections and Infestations Nasopharyngitis 2% 7% 1% 3% 4% Investigations Weight Increased 2% 7% 8% 6% 7% Blood Cortisol Decreased 1% 4% 0% 3% 2% Metabolism and Nutrition Increased Appetite 2% 3% 3% 2% 3% Nervous System Disorders Akathisia 2% 4% 7% 14% 9% Headache 6% 9% 4% 6% 7% Somnolence 0.5% 4% 4% 6% 5% Tremor 2% 4% 2% 5% 4% Dizziness 1% 1% 5% 2% 3% Psychiatric Disorders Anxiety 1% 2% 4% 4% 3% Restlessness 0% 2% 3% 4% 3% * Adverse reactions that occurred in greater than or equal to 2% of brexpiprazole tablets-treated patients and greater incidence than in placebo-treated patients Dose-Related Adverse Reactions in the MDD Trials In Studies 1 and 2, among the adverse reactions that occurred at greater than or equal to 2% incidence in the patients treated with brexpiprazole tablets plus ADT, the incidences of akathisia and restlessness increased with increases in dose. Schizophrenia Adults The safety of brexpiprazole tablets was evaluated in 852 adult patients (18 to 65 years of age) diagnosed with schizophrenia who participated in two 6-week placebo-controlled, fixed-dose clinical trials in which brexpiprazole tablets was administered at daily doses of 1 mg, 2 mg and 4 mg [see Clinical Studies ( 14.2)]. Common Adverse Reactions Adverse reactions associated with brexpiprazole tablets (incidence of 2% or greater and brexpiprazole tablets incidence greater than placebo) during short-term (up to 6 weeks) trials in adult patients with schizophrenia are shown in Table 8. Table 8: Adverse Reactions in Pooled 6-Week Placebo-Controlled, Fixed-Dose Schizophrenia Trials in Adult Patients (Studies 3 and 4)* Placebo (N=368) Brexpiprazole Tablets 1 mg/day (N=120) 2 mg/day (N=368) 4 mg/day (N=364) ALL Brexpiprazole Tablets (N=852) Gastrointestinal Disorders Dyspepsia 2% 6% 2% 3% 3% Diarrhea 2% 1% 3% 3% 3% Investigations Weight Increased 2% 3% 4% 4% 4% Blood Creatinine Phosphokinase Increased 1% 4% 2% 2% 2% Nervous System Disorders Akathisia 5% 4% 5% 7% 6% Tremor 1% 2% 2% 3% 3% Sedation 1% 2% 2% 3% 2% * Adverse reactions that occurred in greater than or equal to 2% of brexpiprazole tablets-treated patients and greater incidence than in placebo-treated patients Extrapyramidal Symptoms Major Depressive Disorder The incidence of reported extrapyramidal symptoms (EPS)-related adverse reactions, excluding akathisia, was 6% for brexpiprazole tablets plus ADT-treated patients versus 3% for placebo plus ADT-treated patients. The incidence of akathisia events for brexpiprazole tablets plus ADT-treated patients was 9% versus 2% for placebo plus ADT-treated patients. In the 6-week placebo-controlled MDD studies, data was objectively collected on the Simpson-Angus Rating Scale (SAS) for EPS, the Barnes Akathisia Rating Scale (BARS) for akathisia and the Abnormal Involuntary Movement Score (AIMS) for dyskinesia. The mean change from baseline at last visit for brexpiprazole tablets plus ADT-treated patients for the SAS, BARS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in brexpiprazole tablets plus ADT-treated patients versus placebo plus ADT-treated patients for the BARS (4% versus 0.6%) and the SAS (4% versus 3%). Schizophrenia The incidence of reported EPS-related adverse reactions, excluding akathisia, was 5% for brexpiprazole tablets-treated patients versus 4% for placebo-treated patients. The incidence of akathisia events for brexpiprazole tablets-treated patients was 6% versus 5% for placebo-treated patients. In the 6-week placebo-controlled, fixed-dose schizophrenia studies in adults, data was objectively collected on the Simpson-Angus Rating Scale (SAS) for EPS, the Barnes Akathisia Rating Scale (BARS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesia. The mean change from baseline at last visit for brexpiprazole tablets-treated patients for the SAS, BARS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in brexpiprazole tablets-treated patients versus placebo for the BARS (2% versus 1%) and the SAS (7% versus 5%). Dystonia Symptoms of dystonia may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. Other Adverse Reactions Observed during the Premarketing Evaluation of Brexpiprazole Tablets Other adverse reactions (greater than or equal to 1% frequency and greater than placebo) within the short-term, placebo-controlled trials in adult patients with MDD and schizophrenia are shown below. The following listing does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo. Eye Disorders: Vision Blurred Gastrointestinal Disorders: Nausea, Dry Mouth, Salivary Hypersecretion, Abdominal Pain, Flatulence Infections and Infestations: Urinary Tract Infection Investigations: Blood Prolactin Increased Musculoskeletal and Connective Tissue Disorders: Myalgia Psychiatric Disorders: Abnormal Dreams, Insomnia Skin and Subcutaneous Tissue Disorders: Hyperhidrosis Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti ® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information. 6.2 Postmarketing Experience The following adverse reaction has been identified during post-approval use of brexpiprazole tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Nervous System disorders: Neuroleptic Malignant Syndrome

4 CONTRAINDICATIONS Brexpiprazole tablets are contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components. Reactions have included rash, facial swelling, urticaria, and anaphylaxis. Known hypersensitivity to brexpiprazole tablets or any of its components ( 4 )

11 DESCRIPTION Brexpiprazole, an atypical antipsychotic, is available as brexpiprazole tablets. Brexpiprazole is 7-{4-[4-(1- Benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1 H )-one. The molecular formula is C 25 H 27 N 3 O 2 S and its molecular weight is 433.57. The chemical structure is: Brexpiprazole tablets are for oral administration and are available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths. Inactive ingredients include microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, propylene glycol, polyethylene glycol. Colorants includes titanium dioxide, iron oxide red (0.25 mg and 3 mg), FD&C Yellow #6 (0.5 mg), iron oxide yellow (1 mg, 2 mg and 3 mg), FD&C Blue #2 (2 mg). structure

2 DOSAGE AND ADMINISTRATION Administer brexpiprazole tablets once daily with or without food. ( 2.1 , 2.2 , 12.3 ) Indication Starting Dose Recommended Dose Maximum Dose MDD Adults ( 2.1 ) 0.5 mg/day or 1 mg/day 2 mg/day 3 mg/day Schizophrenia Adults ( 2.2 ) 1 mg/day 2 to 4 mg/day 4 mg/day Moderate to Severe Hepatic Impairment (Child-Pugh score greater than or equal to 7): Maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophrenia. ( 2.3 ) Moderate, Severe or End-Stage Renal Impairment (CrCl less than 60 mL/minute): Maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophrenia. ( 2.4 ) Known CYP2D6 Poor Metabolizers: Reduce the usual dosage by half. ( 2.5 ) 2.1 Adjunctive Treatment of Major Depressive Disorder (Adults) The recommended starting dosage for brexpiprazole tablets as adjunctive treatment of MDD in adults is 0.5 mg or 1 mg once daily, taken orally with or without food [see Clinical Pharmacology ( 12.3 )]. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for treatment. 2.2 Treatment of Schizophrenia (Adults) Adults The recommended starting dosage for brexpiprazole tablets for the treatment of schizophrenia in adults is 1 mg once daily on Days 1 to 4, taken orally with or without food [see Clinical Pharmacology ( 12.3 )]. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient’s clinical response and tolerability. The recommended target brexpiprazole tablets dosage is 2 mg to 4 mg once daily. The maximum recommended daily dosage is 4 mg. Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti ® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information. 2.3 Dosage Adjustments for Hepatic Impairment For patients with moderate to severe hepatic impairment (Child-Pugh score greater than or equal to 7), the maximum recommended dosage is 2 mg once daily for patients with MDD, and 3 mg once daily for patients with schizophrenia [see Use in Specific Populations ( 8.7 ), Clinical Pharmacology ( 12.3 )]. 2.4 Dosage Adjustments for Renal Impairment For patients with moderate, severe, or end-stage renal impairment (creatinine clearance CrCl less than 60 mL/minute), the maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophrenia [see Use in Specific Populations ( 8.8 ), Clinical Pharmacology ( 12.3 )]. 2.5 Dosage Modifications for CYP2D6 Poor Metabolizers and for Concomitant Use with CYP Inhibitors or Inducers Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers (see Table 1). If the coadministered drug is discontinued, adjust the brexpiprazole tablets dosage to its original level. If the coadministered CYP3A4 inducer is discontinued, reduce the brexpiprazole tablets dosage to the original level over 1 to 2 weeks [see Drug Interactions ( 7.1 ),Clinical Pharmacology ( 12.3 )]. Table 1: Dosage Adjustments of Brexpiprazole Tablets for CYP2D6 Poor Metabolizers and for Concomitant Use with CYP3A4 and CYP2D6 Inhibitors and/or CYP3A4 Inducers *In the clinical trials examining the adjunctive use of brexpiprazole tablets in the treatment of MDD, dosage was not adjusted for strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations, and brexpiprazole tablets may be administered without dosage adjustment in patients with MDD. Factors Adjusted Brexpiprazole Tablets Dosage CYP2D6 Poor Metabolizers CYP2D6 poor metabolizers Administer half of the usual dose. Known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors Administer a quarter of the usual dose. Patients Taking CYP2D6 Inhibitors and/or CYP3A4 Inhibitors Strong CYP2D6 inhibitors* Administer half of the usual dose. Strong CYP3A4 inhibitors Administer half of the usual dose. Strong/moderate CYP2D6 inhibitors with strong/moderate CYP3A4 inhibitors Administer a quarter of the usual dose. Patients Taking CYP3A4 Inducers Strong CYP3A4 inducers Double usual dose over 1 to 2 weeks.

1 INDICATIONS AND USAGE Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults. Brexpiprazole tablets is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 , 14.1 ) Treatment of schizophrenia in adults

9.2 Abuse Animals given access to brexpiprazole tablets did not self-administer the drug, suggesting that brexpiprazole tablets does not have rewarding properties.

9.1 Controlled Substance Brexpiprazole is not a controlled substance.

9.3 Dependence Humans and animals that received chronic brexpiprazole tablets administration did not demonstrate any withdrawal signs upon drug discontinuation. This suggests that brexpiprazole tablets does not produce physical dependence.

9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance Brexpiprazole is not a controlled substance. 9.2 Abuse Animals given access to brexpiprazole tablets did not self-administer the drug, suggesting that brexpiprazole tablets does not have rewarding properties. 9.3 Dependence Humans and animals that received chronic brexpiprazole tablets administration did not demonstrate any withdrawal signs upon drug discontinuation. This suggests that brexpiprazole tablets does not produce physical dependence.

10 OVERDOSAGE There is limited clinical trial experience regarding human overdosage with brexpiprazole tablets. Consult a Certified Poison Control Center ( 1-800-222-1222 or www.poison.org ) for up-to-date guidance and advice regarding a brexpiprazole tablets overdosage. Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers. Charcoal Oral activated charcoal and sorbitol (50 g/240 mL), administered one hour after ingesting oral brexpiprazole, decreased brexpiprazole Cmax and area under the curve (AUC) by approximately 5% to 23% and 31% to 39% respectively; however, there is insufficient information available on the therapeutic potential of activated charcoal in treating an overdose with brexpiprazole tablets. Hemodialysis There is no information on the effect of hemodialysis in treating an overdose with brexpiprazole tablets; hemodialysis is unlikely to be useful because brexpiprazole is highly bound to plasma proteins.

7 DRUG INTERACTIONS * Brexpiprazole tablets may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). Factors Dosage Adjustments for brexpiprazole tablets ( 2.5 ) Strong CYP2D6* or CYP3A4 inhibitors Administer half of usual dose. Strong/moderate CYP2D6 with Strong/moderate CYP3A4 inhibitors Administer a quarter of usual dose. Known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors Administer a quarter of usual dose. Strong CYP3A4 inducers Double the usual dose and further adjust based on clinical response. 7.1 Drugs Having Clinically Important Interactions with Brexpiprazole Tablets Table 9: Clinically Important Drug Interactions with Brexpiprazole Tablets * In the clinical trials examining the adjunctive use of brexpiprazole tablets in the treatment of MDD, dosage was not adjusted for strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations, and brexpiprazole tablets may be administered without dosage adjustment in patients with MDD. Strong CYP3A4 Inhibitors Clinical Impact: Concomitant use of brexpiprazole tablets with strong CYP3A4 inhibitors increased the exposure of brexpiprazole compared to the use of brexpiprazole tablets alone [see Clinical Pharmacology ( 12.3 )]. Intervention: With concomitant use of brexpiprazole tablets with a strong CYP3A4 inhibitor, reduce the brexpiprazole tablets dosage [see Dosage and Administration ( 2.5 )]. Strong CYP2D6 Inhibitors* Clinical Impact: Concomitant use of brexpiprazole tablets with strong CYP2D6 inhibitors increased the exposure of brexpiprazole compared to the use of brexpiprazole tablets alone [see Clinical Pharmacology ( 12.3 )]. Intervention: With concomitant use of brexpiprazole tablets with a strong CYP2D6 inhibitor, reduce the brexpiprazole tablets dosage [see Dosage and Administration ( 2.5 )]. Both CYP3A4 Inhibitors and CYP2D6 Inhibitors Clinical Impact: Concomitant use of brexpiprazole tablets with 1) a strong CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 2) a moderate CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 3) a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor; or 4) a moderate CYP3A4 inhibitor and a moderate CYP2D6 inhibitor, increased the exposure of brexpiprazole compared to the use of brexpiprazole tablets alone [see Clinical Pharmacology ( 12.3 )] . Intervention: With concomitant use of brexpiprazole tablets with 1) a strong CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 2) a moderate CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 3) a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor; or 4) a moderate CYP3A4 inhibitor and a moderate CYP2D6 inhibitor, decrease the brexpiprazole tablets dosage [see Dosage and Administration ( 2.5 )] . Strong CYP3A4 Inducers Clinical Impact: Concomitant use of brexpiprazole tablets and a strong CYP3A4 inducer decreased the exposure of brexpiprazole compared to the use of brexpiprazole tablets alone [see Clinical Pharmacology ( 12.3 )]. Intervention: With concomitant use of brexpiprazole tablets with a strong CYP3A4 inducer, increase the brexpiprazole tablets dosage [see Dosage and Administration ( 2.5 )]. 7.2 Drugs Having No Clinically Important Interactions with Brexpiprazole Tablets Based on pharmacokinetic studies, no dosage adjustment of brexpiprazole tablets is required when administered concomitantly with CYP2B6 inhibitors (e.g., ticlopidine) or gastric pH modifiers (e.g., omeprazole). Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with brexpiprazole tablets.

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of brexpiprazole in the treatment of major depressive disorder or schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT 1A and dopamine D 2 receptors, and antagonist activity at serotonin 5-HT 2A receptors. 12.2 Pharmacodynamics Brexpiprazole has affinity (expressed as K i ) for multiple monoaminergic receptors including serotonin 5-HT 1A (0.12 nM), 5-HT 2A (0.47 nM), 5-HT 2B (1.9 nM), 5-HT 7 (3.7 nM), dopamine D 2 (0.30 nM), D 3 (1.1 nM), and noradrenergic α 1A (3.8 nM), α 1B (0.17 nM), α 1D (2.6 nM), and α 2C (0.59 nM) receptors. Brexpiprazole acts as a partial agonist at the 5-HT 1A , D 2 , and D 3 receptors and as an antagonist at 5-HT 2A , 5-HT 2B , 5-HT 7 , α 1A , α 1B , α 1D , and α 2C receptors. Brexpiprazole also exhibits affinity for histamine H 1 receptor (19 nM) and for muscarinic M 1 receptor (67% inhibition at 10 µM). Cardiac Electrophysiology At a dose 3 times the MRHD for the treatment of schizophrenia and 4 times the MRHD for adjunctive therapy to antidepressants for the treatment of MDD, brexpiprazole tablets does not prolong the QTc interval to any clinically relevant extent. 12.3 Pharmacokinetics Absorption After single-dose administration of brexpiprazole tablets, the peak plasma brexpiprazole concentrations occurred within 4 hours after administration, and the absolute oral bioavailability was 95%. Brexpiprazole steady-state concentrations were attained within 10 to 12 days of dosing. Brexpiprazole tablets can be administered with or without food. Administration of a 4 mg brexpiprazole tablet with a standard high-fat meal did not significantly affect the C max or AUC of brexpiprazole. After single and multiple once daily dose administration, brexpiprazole exposure (C max and AUC) increased in proportion to the dose administered. In vitro studies of brexpiprazole did not indicate that brexpiprazole is a substrate of efflux transporters such as MDRI (P-gp) and BCRP. Distribution The volume of distribution of brexpiprazole following intravenous administration is high (1.56±0.42 L/kg), indicating extravascular distribution. Brexpiprazole is highly protein bound in plasma (greater than 99%) to serum albumin and α1-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment. Based on results of in vitro studies, brexpiprazole protein binding is not affected by warfarin, diazepam, or digitoxin. Elimination Metabolism Based on in vitro metabolism studies of brexpiprazole using recombinant human cytochrome P450 (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4), the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6. In vivo brexpiprazole is metabolized primarily by CYP3A4 and CYP2D6 enzymes. After single- and multiple-dose administrations, brexpiprazole and its major metabolite, DM-3411, were the predominant drug moieties in the systemic circulation. At steady-state, DM-3411 represented 23% to 48% of brexpiprazole exposure (AUC) in plasma. DM-3411 is considered not to contribute to the therapeutic effects of brexpiprazole. Based on in vitro data, brexpiprazole showed little to no inhibition of CYP450 isozymes. Excretion Following a single oral dose of [14C]-labeled brexpiprazole, approximately 25% and 46% of the administered radioactivity was recovered in the urine and feces, respectively. Less than 1% of unchanged brexpiprazole was excreted in the urine, and approximately 14% of the oral dose was recovered unchanged in the feces. Apparent oral clearance of a brexpiprazole oral tablet after once daily administration is 19.8 (±11.4) mL/h/kg. After multiple once-daily administrations of brexpiprazole tablets, the terminal elimination half-lives of brexpiprazole and its major metabolite, DM-3411, were 91 hours and 86 hours, respectively. Studies in Specific Populations Exposure of brexpiprazole in specific populations are summarized in Figure 1. Population pharmacokinetic (PK) analysis indicated exposure of brexpiprazole in patients with moderate renal impairment was higher compared to patients with normal renal function. Figure 1: Effect of Intrinsic Factors on Brexpiprazole Pharmacokinetics Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information. Drug Interaction Studies Effects of other drugs on the exposures of brexpiprazole are summarized in Figure 2. Based on simulation, a 5.1-fold increase in AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors. A 4.8-fold increase in mean AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )]. Figure 2: The Effect of Other Drugs on Brexpiprazole Pharmacokinetics The effects of brexpiprazole tablets on the exposures of other drugs are summarized in Figure 3. Figure 3: The Effect of Brexpiprazole Tablets on Pharmacokinetics of Other Drugs figure1 figure2 figure3

12.1 Mechanism of Action The mechanism of action of brexpiprazole in the treatment of major depressive disorder or schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT 1A and dopamine D 2 receptors, and antagonist activity at serotonin 5-HT 2A receptors.

12.2 Pharmacodynamics Brexpiprazole has affinity (expressed as K i ) for multiple monoaminergic receptors including serotonin 5-HT 1A (0.12 nM), 5-HT 2A (0.47 nM), 5-HT 2B (1.9 nM), 5-HT 7 (3.7 nM), dopamine D 2 (0.30 nM), D 3 (1.1 nM), and noradrenergic α 1A (3.8 nM), α 1B (0.17 nM), α 1D (2.6 nM), and α 2C (0.59 nM) receptors. Brexpiprazole acts as a partial agonist at the 5-HT 1A , D 2 , and D 3 receptors and as an antagonist at 5-HT 2A , 5-HT 2B , 5-HT 7 , α 1A , α 1B , α 1D , and α 2C receptors. Brexpiprazole also exhibits affinity for histamine H 1 receptor (19 nM) and for muscarinic M 1 receptor (67% inhibition at 10 µM). Cardiac Electrophysiology At a dose 3 times the MRHD for the treatment of schizophrenia and 4 times the MRHD for adjunctive therapy to antidepressants for the treatment of MDD, brexpiprazole tablets does not prolong the QTc interval to any clinically relevant extent.

12.3 Pharmacokinetics Absorption After single-dose administration of brexpiprazole tablets, the peak plasma brexpiprazole concentrations occurred within 4 hours after administration, and the absolute oral bioavailability was 95%. Brexpiprazole steady-state concentrations were attained within 10 to 12 days of dosing. Brexpiprazole tablets can be administered with or without food. Administration of a 4 mg brexpiprazole tablet with a standard high-fat meal did not significantly affect the C max or AUC of brexpiprazole. After single and multiple once daily dose administration, brexpiprazole exposure (C max and AUC) increased in proportion to the dose administered. In vitro studies of brexpiprazole did not indicate that brexpiprazole is a substrate of efflux transporters such as MDRI (P-gp) and BCRP. Distribution The volume of distribution of brexpiprazole following intravenous administration is high (1.56±0.42 L/kg), indicating extravascular distribution. Brexpiprazole is highly protein bound in plasma (greater than 99%) to serum albumin and α1-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment. Based on results of in vitro studies, brexpiprazole protein binding is not affected by warfarin, diazepam, or digitoxin. Elimination Metabolism Based on in vitro metabolism studies of brexpiprazole using recombinant human cytochrome P450 (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4), the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6. In vivo brexpiprazole is metabolized primarily by CYP3A4 and CYP2D6 enzymes. After single- and multiple-dose administrations, brexpiprazole and its major metabolite, DM-3411, were the predominant drug moieties in the systemic circulation. At steady-state, DM-3411 represented 23% to 48% of brexpiprazole exposure (AUC) in plasma. DM-3411 is considered not to contribute to the therapeutic effects of brexpiprazole. Based on in vitro data, brexpiprazole showed little to no inhibition of CYP450 isozymes. Excretion Following a single oral dose of [14C]-labeled brexpiprazole, approximately 25% and 46% of the administered radioactivity was recovered in the urine and feces, respectively. Less than 1% of unchanged brexpiprazole was excreted in the urine, and approximately 14% of the oral dose was recovered unchanged in the feces. Apparent oral clearance of a brexpiprazole oral tablet after once daily administration is 19.8 (±11.4) mL/h/kg. After multiple once-daily administrations of brexpiprazole tablets, the terminal elimination half-lives of brexpiprazole and its major metabolite, DM-3411, were 91 hours and 86 hours, respectively. Studies in Specific Populations Exposure of brexpiprazole in specific populations are summarized in Figure 1. Population pharmacokinetic (PK) analysis indicated exposure of brexpiprazole in patients with moderate renal impairment was higher compared to patients with normal renal function. Figure 1: Effect of Intrinsic Factors on Brexpiprazole Pharmacokinetics Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information. Drug Interaction Studies Effects of other drugs on the exposures of brexpiprazole are summarized in Figure 2. Based on simulation, a 5.1-fold increase in AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors. A 4.8-fold increase in mean AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )]. Figure 2: The Effect of Other Drugs on Brexpiprazole Pharmacokinetics The effects of brexpiprazole tablets on the exposures of other drugs are summarized in Figure 3. Figure 3: The Effect of Brexpiprazole Tablets on Pharmacokinetics of Other Drugs figure1 figure2 figure3

20221213

4

3 DOSAGE FORMS AND STRENGTHS Brexpiprazole tablets are available in 6 strengths: 0.25 mg tablets are brown colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “6” on other side. 0.5 mg tablets are orange colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “5” on other side. 1 mg tablets are yellow colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “1” on other side. 2 mg tablets are light green to green colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “2” on other side. 3 mg tablets are pink colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “3” on other side. 4 mg tablets are white to off-white colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “4” on other side. Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg (3)

Brexpiprazole Brexpiprazole BREXPIPRAZOLE BREXPIPRAZOLE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE HYDROXYPROPYL CELLULOSE, UNSPECIFIED LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TALC TITANIUM DIOXIDE PROPYLENE GLYCOL FERRIC OXIDE RED biconvex BX;6 Brexpiprazole Brexpiprazole BREXPIPRAZOLE BREXPIPRAZOLE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE HYDROXYPROPYL CELLULOSE, UNSPECIFIED LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TALC TITANIUM DIOXIDE PROPYLENE GLYCOL FD&C YELLOW NO. 6 biconvex BX;5 Brexpiprazole Brexpiprazole BREXPIPRAZOLE BREXPIPRAZOLE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE HYDROXYPROPYL CELLULOSE, UNSPECIFIED LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TALC TITANIUM DIOXIDE PROPYLENE GLYCOL FERRIC OXIDE YELLOW biconvex BX;1 Brexpiprazole Brexpiprazole BREXPIPRAZOLE BREXPIPRAZOLE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE HYDROXYPROPYL CELLULOSE, UNSPECIFIED LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED FERRIC OXIDE YELLOW FD&C BLUE NO. 2 light green to green biconvex BX;2 Brexpiprazole Brexpiprazole BREXPIPRAZOLE BREXPIPRAZOLE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE HYDROXYPROPYL CELLULOSE, UNSPECIFIED LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED FERRIC OXIDE YELLOW FERRIC OXIDE RED biconvex BX;3 Brexpiprazole Brexpiprazole BREXPIPRAZOLE BREXPIPRAZOLE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE HYDROXYPROPYL CELLULOSE, UNSPECIFIED LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED white to off-white biconvex BX;4

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Lifetime carcinogenicity studies were conducted in ICR mice and Sprague Dawley rats. Brexpiprazole was administered orally for two years to male and female mice at doses of 0.75 mg/kg/day, 2 mg/kg/day, and 5 mg/kg/day (0.9 to 6.1 times the oral MRHD of 4 mg/day based on mg/m 2 body surface area) and to male and female rats at doses of 1 mg/kg, 3 mg/kg, and 10 mg/kg and 3 mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day, respectively (2.4 to 24 and 7.3 to 73 times the oral MRHD, males and females). In female mice, the incidence of mammary gland adenocarcinoma was increased at all doses, and the incidence of adenosquamous carcinoma was increased at 2.4 and 6.1 times the MRHD. No increase in the incidence of tumors was observed in male mice. In the rat study, brexpiprazole was not carcinogenic in either sex at doses up to 73 times the MRHD. Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin mediated. The potential for increasing serum prolactin level of brexpiprazole was shown in both mice and rats. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown. Mutagenesis Brexpiprazole was not mutagenic when tested in the in vitro bacterial reverse mutation assay (Ames test). Brexpiprazole was negative for clastogenic activity in the in vivo micronucleus assay in rats and was not genotoxic in the in vivo/in vitro unscheduled DNA synthesis assay in rats. In vitro with mammalian cells brexpiprazole was clastogenic but only at doses that induced cytotoxicity. Based on a weight of evidence, brexpiprazole is not considered to present a genotoxic risk to humans. Impairment of Fertility Female rats were treated with oral doses of 0.3 mg/kg/day, 3 mg/kg/day, or 30 mg/kg/day (0.7, 7.3, and 73 times the oral MRHD on a mg/m 2 basis) prior to mating with untreated males and continuing through conception and implantation. Estrus cycle irregularities and decreased fertility were observed at 3 mg/kg/day and 30 mg/kg/day. Prolonged duration of pairing and increased preimplantation losses were observed at 30 mg/kg/day. Male rats were treated with oral doses of 3 mg/kg/day, 10 mg/kg/day, or 100 mg/kg/day (7.3, 24, and 240 times the oral MRHD on a mg/m 2 basis) for 63 days prior to mating with untreated females and throughout the 14 days of mating. No differences were observed in the duration of mating or fertility indices in males at any dose of brexpiprazole.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Lifetime carcinogenicity studies were conducted in ICR mice and Sprague Dawley rats. Brexpiprazole was administered orally for two years to male and female mice at doses of 0.75 mg/kg/day, 2 mg/kg/day, and 5 mg/kg/day (0.9 to 6.1 times the oral MRHD of 4 mg/day based on mg/m 2 body surface area) and to male and female rats at doses of 1 mg/kg, 3 mg/kg, and 10 mg/kg and 3 mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day, respectively (2.4 to 24 and 7.3 to 73 times the oral MRHD, males and females). In female mice, the incidence of mammary gland adenocarcinoma was increased at all doses, and the incidence of adenosquamous carcinoma was increased at 2.4 and 6.1 times the MRHD. No increase in the incidence of tumors was observed in male mice. In the rat study, brexpiprazole was not carcinogenic in either sex at doses up to 73 times the MRHD. Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin mediated. The potential for increasing serum prolactin level of brexpiprazole was shown in both mice and rats. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown. Mutagenesis Brexpiprazole was not mutagenic when tested in the in vitro bacterial reverse mutation assay (Ames test). Brexpiprazole was negative for clastogenic activity in the in vivo micronucleus assay in rats and was not genotoxic in the in vivo/in vitro unscheduled DNA synthesis assay in rats. In vitro with mammalian cells brexpiprazole was clastogenic but only at doses that induced cytotoxicity. Based on a weight of evidence, brexpiprazole is not considered to present a genotoxic risk to humans. Impairment of Fertility Female rats were treated with oral doses of 0.3 mg/kg/day, 3 mg/kg/day, or 30 mg/kg/day (0.7, 7.3, and 73 times the oral MRHD on a mg/m 2 basis) prior to mating with untreated males and continuing through conception and implantation. Estrus cycle irregularities and decreased fertility were observed at 3 mg/kg/day and 30 mg/kg/day. Prolonged duration of pairing and increased preimplantation losses were observed at 30 mg/kg/day. Male rats were treated with oral doses of 3 mg/kg/day, 10 mg/kg/day, or 100 mg/kg/day (7.3, 24, and 240 times the oral MRHD on a mg/m 2 basis) for 63 days prior to mating with untreated females and throughout the 14 days of mating. No differences were observed in the duration of mating or fertility indices in males at any dose of brexpiprazole.

ANDA213718

Brexpiprazole

Brexpiprazole

27241-209

HUMAN PRESCRIPTION DRUG

ORAL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 27241-204-30 0.25 mg 30 Tablets Brexpiprazole Tablets PHARMACIST: DISPENSE THE ACCOMPANYNG MEDICATION GUIDE TO EACH PATIENT Rx Only ajanta NDC 27241-205-30 0.5 mg 30 Tablets Brexpiprazole Tablets PHARMACIST: DISPENSE THE ACCOMPANYNG MEDICATION GUIDE TO EACH PATIENT Rx Only ajanta NDC 27241-206-30 1 mg 30 Tablets Brexpiprazole Tablets PHARMACIST: DISPENSE THE ACCOMPANYNG MEDICATION GUIDE TO EACH PATIENT Rx Only ajanta NDC 27241-207-30 2 mg 30 Tablets Brexpiprazole Tablets PHARMACIST: DISPENSE THE ACCOMPANYNG MEDICATION GUIDE TO EACH PATIENT Rx Only ajanta NDC 27241-208-30 3 mg 30 Tablets Brexpiprazole Tablets PHARMACIST: DISPENSE THE ACCOMPANYNG MEDICATION GUIDE TO EACH PATIENT Rx Only ajanta NDC 27241-209-30 4 mg 30 Tablets Brexpiprazole Tablets PHARMACIST: DISPENSE THE ACCOMPANYNG MEDICATION GUIDE TO EACH PATIENT Rx Only ajanta 0.25mg 0.5mg 1mg 2mg 3mg 4mg

Boxed Warning 12/2021 Warnings and Precautions ( 5.6 ) 12/2021

17 PATIENT COUNSELING INFORMATION Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide). Suicidal Thoughts and Behaviors Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down, and instruct them to report such symptoms to the healthcare provider [ see Boxed Warning, Warnings and Precautions ( 5.2 )]. Dosage and Administration Advise patients that brexpiprazole tablets can be taken with or without food. Advise patients regarding importance of following dosage escalation instructions [see Dosage and Administration ( 2.1 ), ( 2.2 )]. Neuroleptic Malignant Syndrome (NMS) Counsel patients about a potentially fatal adverse reaction - neuroleptic malignant syndrome (NMS) - that has been reported in association with administration of antipsychotic drugs. Advise patients to contact a healthcare provider or report to the emergency room if they experience signs or symptoms of NMS [see Warnings and Precautions ( 5.4 )]. Tardive Dyskinesia Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur [see Warnings and Precautions ( 5.5 )]. Metabolic Changes Educate patients about the risk of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight [see Warnings and Precautions ( 5.6 )]. Pathological Gambling and Other Compulsive Behaviors Advise patients and their caregivers of the possibility that they may experience compulsive urges to shop, intense urges to gamble, compulsive sexual urges, binge eating and/or other compulsive urges and the inability to control these urges while taking brexpiprazole tablets. In some cases, but not all, the urges were reported to have stopped when the dose was reduced or stopped [see Warnings and Precautions ( 5.7 )]. Leukopenia, Neutropenia and Agranulocytosis Advise patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia that they should have their CBC monitored while taking brexpiprazole tablets [see Warnings and Precautions ( 5.8 )]. Orthostatic Hypotension and Syncope Educate patients about the risk of orthostatic hypotension and syncope, especially early in treatment, and also at times of reinitiating treatment or increases in dosage [see Warnings and Precautions ( 5.9 )]. Heat Exposure and Dehydration Counsel patients regarding appropriate care in avoiding overheating and dehydration [see Warnings and Precautions( 5.12 )]. Interference with Cognitive and Motor Performance Caution patients about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that brexpiprazole tablets therapy does not adversely affect their ability to engage in such activities [see Warnings and Precautions ( 5.14 )]. Concomitant Medications Advise patients to inform their healthcare providers of any changes to their current prescription or over-the-counter medications because there is a potential for clinically significant interactions [see Drug Interactions ( 7.1 )]. Pregnancy Advise patients that third trimester use of brexpiprazole tablets may cause extrapyramidal and/or withdrawal symptoms in a neonate and to notify their healthcare provider with a known or suspected pregnancy. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to brexpiprazole tablets during pregnancy [see Use in Specific Populations ( 8.1 )]. Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807. Made in INDIA. #All trademarks are the properties of their respective owners Revised: 12/2022

MEDICATION GUIDE Brexpiprazole (breks PIP ray zole) Tablets What is the most important information I should know about brexpiprazole tablets? Brexpiprazole tablets may cause serious side effects, including: Increased risk of death in elderly people with dementia-related psychosis. Medicines like brexpiprazole tablets can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Brexpiprazole tablets are not approved for the treatment of people with dementia-related psychosis. Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when brexpiprazole tablets or the antidepressant medicine is started or when the dose is changed. Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call a healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you: o thoughts about suicide or dying o attempts to commit suicide o new or worsening depression o new or worsening anxiety o feeling very agitated or restless o panic attacks o trouble sleeping (insomnia) o new or worsening irritability o acting aggressive, being angry, or violent o acting on dangerous impulses o an extreme increase in activity or talking (mania) o other unusual changes in behavior or mood What are brexpiprazole tablets? Brexpiprazole tablets are prescription medicine used: with other antidepressant medicines to treat major depressive disorder (MDD) in adults. to treat schizophrenia in adults It is not known if brexpiprazole tablets are safe and effective in children with MDD. It is not known if brexpiprazole tablets are safe and effective in children under 13 years of age with schizophrenia. Do not take brexpiprazole tablets if you are allergic to brexpiprazole or any of the ingredients in brexpiprazole tablets. See the end of this Medication Guide for a complete list of ingredients in brexpiprazole tablets. Before taking brexpiprazole tablets, tell your healthcare provider about all of your medical conditions, including if you: have or have had heart problems or a stroke have or have had low or high blood pressure have or have had diabetes or high blood sugar or a family history of diabetes or high blood sugar. Your healthcare provider should check your blood sugar before you start brexpiprazole tablets and during treatment with brexpiprazole tablets. have or have had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low levels of HDL cholesterol have or have had seizures (convulsions) have or have had kidney or liver problems have or have had a low white blood cell count are pregnant or plan to become pregnant. Brexpiprazole tablets may harm your unborn baby. Taking brexpiprazole tablets during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with brexpiprazole tablets. If you become pregnant during treatment with brexpiprazole tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. are breastfeeding or plan to breastfeed. It is not known if brexpiprazole passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with brexpiprazole tablets. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Brexpiprazole tablets and other medicines may affect each other causing possible serious side effects. Brexpiprazole tablets may affect the way other medicines work, and other medicines may affect how brexpiprazole tablets works. Your healthcare provider can tell you if it is safe to take brexpiprazole tablets with your other medicines. Do not start or stop any medicines during treatment with brexpiprazole tablets without first talking to your healthcare provider. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take brexpiprazole tablets? Take brexpiprazole tablets exactly as your healthcare provider tells you to take it. Your healthcare provider may change your dose if needed. Do not change the dose or stop taking brexpiprazole tablets without first talking to your healthcare provider. Take brexpiprazole tablets 1 time each day with or without food. If you take too much brexpiprazole tablets, call your healthcare provider or a certified Poison Control Center at 1-800-222-1222 or go to www.poison.org, or go to the nearest hospital emergency room right away. What should I avoid while taking brexpiprazole tablets? Do not drive a car, operate machinery, or do other dangerous activities until you know how brexpiprazole tablets affects you. Brexpiprazole tablets may make you feel drowsy. Do not become too hot or dehydrated during treatment with brexpiprazole tablets Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water What are the possible side effects of brexpiprazole tablets? Brexpiprazole tablets may cause serious side effects, including: See “What is the most important information I should know about brexpiprazole tablets?” Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death. Neuroleptic Malignant Syndrome (NMS) is a serious condition that can lead to death: Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS: high fever changes in your breathing, heart rate, and blood pressure. stiff muscles confusion increased sweating Uncontrolled body movements (tardive dyskinesia): Brexpiprazole tablets may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking brexpiprazole tablets. Tardive dyskinesia may also start after you stop taking brexpiprazole tablets. Problems with your metabolism such as: high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take brexpiprazole tablets. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before you start, or soon after you start brexpiprazole tablets and then regularly during long term treatment with brexpiprazole tablets. Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with brexpiprazole tablets:  feel very thirsty feel very hungry feel sick to your stomach feel weak or tired need to urinate more than usual feel confused, or your breath smells fruity increased fat levels (cholesterol and triglycerides) in your blood. Your healthcare provider should check the fat levels in your blood before you start, or soon after you start brexpiprazole tablets, and then periodically during treatment with brexpiprazole tablets. weight gain. You and your healthcare provider should check your weight before you start and often during treatment with brexpiprazole tablets. Unusual and uncontrollable (compulsive) urges. Some people taking brexpiprazole tablets have had strong unusual urges, to gamble and gambling that cannot be controlled (compulsive gambling). Other compulsive urges include sexual urges, shopping, and eating or binge eating. If you or your family members notice that you are having unusual strong urges, talk to your healthcare provider. Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with brexpiprazole tablets. Decreased blood pressure (orthostatic hypotension). You may feel lightheaded or faint when you rise too quickly from a sitting or lying position. Falls. Brexpiprazole tablets may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries. Seizures (convulsions) Problems controlling your body temperature so that you feel too warm. See “What should I avoid while taking brexpiprazole tablets?” Difficulty swallowing that can cause food or liquid to get into your lungs Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. See “What should I avoid while taking brexpiprazole tablets?” The most common side effects of brexpiprazole tablets include weight gain and restlessness or feeling like you need to move (akathisia). These are not all the possible side effects of brexpiprazole tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store brexpiprazole tablets? Store brexpiprazole tablets at room temperature, between 68°F to 77°F (20°C to 25°C). Keep brexpiprazole tablets and all medicines out of the reach of children. General information about the safe and effective use of brexpiprazole tablets. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use brexpiprazole tablets for a condition for which it was not prescribed. Do not give brexpiprazole tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about brexpiprazole tablets that is written for healthcare professionals. What are the ingredients in brexpiprazole tablets? Active ingredient: brexpiprazole Inactive ingredients: microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, propylene glycol, polyethylene glycol. Colorants includes titanium dioxide, iron oxide red (0.25 mg and 3 mg), FD&C Yellow #6 (0.5 mg), iron oxide yellow (1 mg, 2 mg and 3 mg), FD&C Blue #2 (2 mg). Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti ® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information. Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807. Made in INDIA. #All trademarks are the properties of their respective owners This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: 12/2022

14 CLINICAL STUDIES 14.1 Adjunctive Treatment of Major Depressive Disorder The efficacy of brexpiprazole tablets in the adjunctive treatment of major depressive disorder (MDD) was evaluated in two 6-week double-blind, placebo-controlled, fixed-dose trials of adult patients meeting DSM-IV-TR criteria for MDD, with or without symptoms of anxiety, who had an inadequate response to prior antidepressant therapy (1 to 3 courses) in the current episode and who had also demonstrated an inadequate response throughout the 8 weeks of prospective antidepressant treatment (with escitalopram, fluoxetine, paroxetine controlled-release, sertraline, duloxetine delayed release, or venlafaxine extended release). Inadequate response during the prospective antidepressant treatment phase was defined as having persistent symptoms without substantial improvement throughout the course of treatment. Patients in Study 228 (hereafter “Study 1”) were randomized to brexpiprazole tablets 2 mg once a day or placebo. Patients in Study 227 (hereafter “Study 2”) were randomized to brexpiprazole tablets 1 mg or 3 mg once a day or placebo. For patients randomized to brexpiprazole tablets, all patients initiated treatment at 0.5 mg once daily during Week 1. At Week 2, the brexpiprazole tablets dosage was increased to 1 mg in all treatment groups, and either maintained at 1 mg or increased to 2 mg or 3 mg once daily, based on treatment assignment, from Week 3 onwards. The dosages were then maintained for the 4 remaining weeks. The primary endpoint was change from baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-related scale used to assess the degree of depressive symptomatology, with 0 representing no symptoms and 60 representing worst symptoms. At randomization, the mean MADRS total score was 27. In Studies 1 and 2, brexpiprazole tablets (plus ADT) 2 mg/day and 3 mg/day were superior to placebo plus ADT in reducing mean MADRS total scores. Results from the primary efficacy parameters for both fixed dose trials are shown below in Table 10. Figure 4 below shows the time course of response based on the primary efficacy measure (MADRS) in Study 1. Table 10: Summary of Efficacy Results for Studies 1 and 2 for the Adjunctive Treatment of MDD SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval * Dosages statistically significantly superior to placebo a Difference (drug minus placebo) in least-squares mean change from baseline Study Treatment Group N Primary Efficacy Measure: MADRS Mean Baseline Score (SD) LS Mean Change From Baseline (SE) Placebo-Subtracted Difference a (95% CI) 1 Brexpiprazole Tablets (2 mg/day) +ADT* Placebo +ADT 175 178 26.9(5.7) 27.3(5.6) -8.4(0.6) -5.2(0.6) -3.2(-4.9,-1.5) -- 2 Brexpiprazole Tablets (1 mg/day) +ADT 211 26.5(5.6) -7.6(0.5) -1.3 (-2.7,0.1) Brexpiprazole Tablets (3 mg/day) +ADT 213 26.5(5.3) -8.3(0.5) -2.0(-3.4, -0.5) Placebo + ADT 203 26.5(5.2) -6.3(0.5) -- An examination of population subgroups did not suggest differential response based on age, gender, race or choice of prospective antidepressant. Figure 4: Change from Baseline in MADRS Total Score by Study Visit (Week) in Patients with MDD in Adults (Study 1) figure4 14.2 Schizophrenia The efficacy of brexpiprazole tablets in the treatment of adults with schizophrenia was demonstrated in two 6-week randomized, double-blind, placebo-controlled, fixed-dose clinical trials in patients who met DSM-IV-TR criteria for schizophrenia. In both studies, Study 231 (hereafter “Study 3”) and Study 230 (hereafter “Study 4”), patients were randomized to brexpiprazole tablets 2 or 4 mg once per day or placebo. Patients in the brexpiprazole tablets groups initiated treatment at 1 mg once daily on Days 1 to 4. The brexpiprazole tablets dosage was increased to 2 mg on Days 5 to 7. The dosage was then either maintained at 2 mg once daily or increased to 4 mg once daily, depending on treatment assignment, for the 5 remaining weeks. The primary efficacy endpoint of both trials was the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score. The PANSS is a 30-item scale that measures positive symptoms of schizophrenia (7 items), negative symptoms of schizophrenia (7 items), and general psychopathology (16 items), each rated on a scale of 1 (absent) to 7 (extreme); the total PANSS scores range from 30 (best) to 210 (worst). In Study 3, brexpiprazole tablets at both 2 mg/day and 4 mg/day was superior to placebo on the PANSS total score. In Study 4, brexpiprazole tablets 4 mg/day was superior to placebo on the PANSS total score (Table 11). Figure 5 shows the time course of response based on the primary efficacy measure (change from baseline in PANSS total score) in Study 3. Examination of population subgroups based on age, gender and race did not suggest differential responsiveness Table 11: Summary of Efficacy Results for Studies of Schizophrenia in Adults (Studies 3 and 4) SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval * Dosages statistically significantly superior to placebo a Difference (drug minus placebo) in least-squares mean change from baseline Study Treatment Group N Primary Efficacy Measure: PANSS Mean Baseline Score (SD) LS Mean Change From Baseline (SE) Placebo-Subtracted Difference a (95% CI) 3 Brexpiprazole Tablets (2 mg/day)* 180 95.9(13.8) -20.7(1.5) -8.7 (-13.1, -4.4) Brexpiprazole Tablets (4 mg/day)* 178 94.7(12.1) -19.7(1.5) -7.6 (-12.0, -3.1) Placebo 178 95.7(11.5) -12.0(1.6) -- 4 Brexpiprazole Tablets (2 mg/day) 179 96.3(12.9) -16.6(1.5) -3.1(-7.2,1.1) Brexpiprazole Tablets (4 mg/day)* 181 95.0(12.4) -20.0(1.5) -6.5(-10.6,-2.4) Placebo 180 94.6(12.8) -13.5(1.5) -- Figure 5: Change from Baseline in PANSS Total Score by Study Visit (Week) in Adult Patients with Schizophrenia (Study 3) The safety and efficacy of brexpiprazole tablets as maintenance treatment in adults with schizophrenia aged 18 to 65 years were demonstrated in the maintenance phase of a randomized withdrawal trial (Study 331-10-232, hereafter “Study 5”). Patients were stabilized for at least 12 weeks on 1 mg/day to 4 mg/day of brexpiprazole tablets (N=202). They were then randomized in the double-blind treatment phase to either continue brexpiprazole tablets at their achieved stable dose (N=97), or to switch to placebo (N=105). The primary endpoint in Study 5 was time from randomization to impending relapse during the double-blind phase, defined as: 1) Clinical Global Improvement score of greater than or equal to 5 (minimally worse) and an increase to a score greater than 4 on PANSS conceptual disorganization, hallucinatory behavior, suspiciousness, or unusual thought content items, with either a greater than or equal to 2 increase on a specific item or greater than or equal to 4 point increase on the combined four PANSS items, 2) hospitalization due to worsening of psychotic symptoms, 3) current suicidal behavior, or 4) violent/aggressive behavior. A pre-specified interim analysis demonstrated a statistically significantly longer time to relapse in patients randomized to the brexpiprazole tablets group compared to placebo-treated patients. The trial was subsequently terminated early because maintenance of efficacy had been demonstrated. The Kaplan-Meier curves of the cumulative proportion of patients with relapse during the double-blind treatment phase for brexpiprazole tablets and placebo groups are shown in Figure 6. The key secondary endpoint, the proportion of patients who met the criteria for impending relapse, was statistically significantly lower in brexpiprazole tablets-treated patients compared with placebo group. Figure 6: Kaplan-Meier Estimation of Percent Impending Relapse in Study 5 Note: A total of 202 patients were randomized. Among them, one placebo patient did not take investigational medicinal product and one brexpiprazole patient did not have post-randomization efficacy evaluations. These two patients were excluded from the efficacy analysis. figure5 figure6

8.5 Geriatric Use Clinical studies of the efficacy of brexpiprazole tablets did not include any patients aged 65 or older to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, and cardiac function, concomitant diseases, and other drug therapy. Based on the results of a safety, tolerability, and pharmacokinetics trial, the pharmacokinetics of once daily oral administration of brexpiprazole (up to 3 mg/day for 14 days) as an adjunct therapy in the treatment of elderly patients (70 to 85 years old, N=11) with MDD were comparable to those observed in adult patients with MDD. Antipsychotic drugs increase the risk of death in elderly patients with dementia-related psychosis. Brexpiprazole tablets are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning , Warnings and Precautions ( 5.1 )].

8.2 Lactation Risk Summary Lactation studies have not been conducted to assess the presence of brexpiprazole in human milk, the effects of brexpiprazole on the breastfed infant, or the effects of brexpiprazole on milk production. Brexpiprazole is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for brexpiprazole tablets and any potential adverse effects on the breastfed infant from brexpiprazole tablets or from the underlying maternal condition.

8.4 Pediatric Use Major Depressive Disorder Safety and effectiveness in pediatric patients with major depressive disorder have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning, Warnings and Precautions ( 5.2 )]. Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information.

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to brexpiprazole tablets during pregnancy. For more information contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. Risk Summary Adequate and well-controlled studies have not been conducted with brexpiprazole tablets in pregnant women to inform drug-associated risks. However, neonates whose mothers are exposed to antipsychotic drugs, like brexpiprazole tablets, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. In animal reproduction studies, no teratogenicity was observed with oral administration of brexpiprazole to pregnant rats and rabbits during organogenesis at doses up to 73 and 146 times, respectively, of maximum recommended human dose (MRHD) of 4 mg/day on a mg/m 2 basis. However, when pregnant rats were administered brexpiprazole during the period of organogenesis through lactation, the number of perinatal deaths of pups was increased at 73 times the MRHD [see Data] . The background risk of major birth defects and miscarriage for the indicated population(s) is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder, have been reported in neonates whose mothers were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Data Animal Data Pregnant rats were treated with oral doses of 3 mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day (7.3, 24, and 73 times the MRHD on a mg/m 2 basis) of brexpiprazole during the period of organogenesis. Brexpiprazole was not teratogenic and did not cause adverse developmental effects at doses up to 73 times the MRHD. Pregnant rabbits were treated with oral doses of 10 mg/kg/day, 30 mg/kg/day, and 150 mg/kg/day (49, 146, and 730 times the MRHD) of brexpiprazole during the period of organogenesis. Brexpiprazole was not teratogenic and did not cause adverse developmental effects at doses up to 146 times the MRHD. Findings of decreased body weight, retarded ossification, and increased incidences of visceral and skeletal variations were observed in fetuses at 730 times the MRHD, a dose that induced maternal toxicity. In a study in which pregnant rats were administered oral doses of 3 mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day (7.3, 24, and 73 times the MRHD) during the period of organogenesis and through lactation, the number of live-born pups was decreased, and early postnatal deaths increased at a dose 73 times the MRHD. Impaired nursing by dams, and low birth weight and decreased body weight gain in pups were observed at 73 times, but not at 24 times, the MRHD.

8 USE IN SPECIFIC POPULATIONS Pregnancy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure ( 8.1 ) Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti ® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, Ltd.’s marketing exclusivity rights, this drug product is not labeled with that information. 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to brexpiprazole tablets during pregnancy. For more information contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. Risk Summary Adequate and well-controlled studies have not been conducted with brexpiprazole tablets in pregnant women to inform drug-associated risks. However, neonates whose mothers are exposed to antipsychotic drugs, like brexpiprazole tablets, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. In animal reproduction studies, no teratogenicity was observed with oral administration of brexpiprazole to pregnant rats and rabbits during organogenesis at doses up to 73 and 146 times, respectively, of maximum recommended human dose (MRHD) of 4 mg/day on a mg/m 2 basis. However, when pregnant rats were administered brexpiprazole during the period of organogenesis through lactation, the number of perinatal deaths of pups was increased at 73 times the MRHD [see Data] . The background risk of major birth defects and miscarriage for the indicated population(s) is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder, have been reported in neonates whose mothers were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Data Animal Data Pregnant rats were treated with oral doses of 3 mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day (7.3, 24, and 73 times the MRHD on a mg/m 2 basis) of brexpiprazole during the period of organogenesis. Brexpiprazole was not teratogenic and did not cause adverse developmental effects at doses up to 73 times the MRHD. Pregnant rabbits were treated with oral doses of 10 mg/kg/day, 30 mg/kg/day, and 150 mg/kg/day (49, 146, and 730 times the MRHD) of brexpiprazole during the period of organogenesis. Brexpiprazole was not teratogenic and did not cause adverse developmental effects at doses up to 146 times the MRHD. Findings of decreased body weight, retarded ossification, and increased incidences of visceral and skeletal variations were observed in fetuses at 730 times the MRHD, a dose that induced maternal toxicity. In a study in which pregnant rats were administered oral doses of 3 mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day (7.3, 24, and 73 times the MRHD) during the period of organogenesis and through lactation, the number of live-born pups was decreased, and early postnatal deaths increased at a dose 73 times the MRHD. Impaired nursing by dams, and low birth weight and decreased body weight gain in pups were observed at 73 times, but not at 24 times, the MRHD. 8.2 Lactation Risk Summary Lactation studies have not been conducted to assess the presence of brexpiprazole in human milk, the effects of brexpiprazole on the breastfed infant, or the effects of brexpiprazole on milk production. Brexpiprazole is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for brexpiprazole tablets and any potential adverse effects on the breastfed infant from brexpiprazole tablets or from the underlying maternal condition. 8.4 Pediatric Use Major Depressive Disorder Safety and effectiveness in pediatric patients with major depressive disorder have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning, Warnings and Precautions ( 5.2 )]. Pediatric use information is approved for Otsuka Pharmaceutical Company, Ltd.’s Rexulti® (brexpiprazole) tablets. However, due to Otsuka Pharmaceutical Company, LTD.’s marketing exclusivity rights, this drug product is not labeled with that information. 8.5 Geriatric Use Clinical studies of the efficacy of brexpiprazole tablets did not include any patients aged 65 or older to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, and cardiac function, concomitant diseases, and other drug therapy. Based on the results of a safety, tolerability, and pharmacokinetics trial, the pharmacokinetics of once daily oral administration of brexpiprazole (up to 3 mg/day for 14 days) as an adjunct therapy in the treatment of elderly patients (70 to 85 years old, N=11) with MDD were comparable to those observed in adult patients with MDD. Antipsychotic drugs increase the risk of death in elderly patients with dementia-related psychosis. Brexpiprazole tablets are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning , Warnings and Precautions ( 5.1 )]. 8.6 CYP2D6 Poor Metabolizers Dosage adjustment is recommended in known CYP2D6 poor metabolizers, because these patients have higher brexpiprazole concentrations than normal metabolizers of CYP2D6. Approximately 8% of Caucasians and 3% to 8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.3 )]. 8.7 Hepatic Impairment Reduce the maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh score greater than or equal to 7). Patients with moderate to severe hepatic impairment (Child-Pugh score greater than or equal to 7) generally had higher exposure to brexpiprazole than patients with normal hepatic function [see Clinical Pharmacology ( 12.3 )] . Greater exposure may increase the risk of brexpiprazole tablets-associated adverse reactions [see Dosage and Administration ( 2.3 )]. 8.8 Renal Impairment Reduce the maximum recommended dosage in patients with moderate, severe, or end-stage renal impairment (CrCl less than 60 mL/minute). Patients with impaired renal function (CrCl less than 60 mL/minute) had higher exposure to brexpiprazole than patients with normal renal function [see Clinical Pharmacology ( 12.3 )] . Greater exposure may increase the risk of brexpiprazole tablets-associated adverse reactions [see Dosage and Administration ( 2.4 )]. 8.9 Other Specific Populations No dosage adjustment for brexpiprazole tablets is required on the basis of a patient’s sex, race, or smoking status [see Clinical Pharmacology ( 12.3 )].

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Brexpiprazole tablets have markings on both the side, and are available in the following strengths and package configurations (see below): 0.25 mg tablets are brown colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “6” on other side. NDC 27241-204-30 Bottles of 30 0.5 mg tablets are orange colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “5” on other side. NDC 27241-205-30 Bottles of 30 1 mg tablets are yellow colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “1” on other side. NDC 27241-206-30 Bottles of 30 2 mg tablets are light green to green colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “2” on other side. NDC 27241-207-30 Bottles of 30 3 mg tablets are pink colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “3” on other side. NDC 27241-208-30 Bottles of 30 4 mg tablets are white to off-white colored, round, biconvex, film-coated tablet, debossed with “BX” on one side and “4” on other side. NDC 27241-209-30 Bottles of 30 16.2 Storage Store brexpiprazole tablets at 20°C t o 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Brexpiprazole tablets are not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger in short-term studies. Monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of brexpiprazole tablets have not been established in pediatric patients with MDD [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.4 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. Brexpiprazole tablets are not approved for the treatment of patients with dementia-related psychosis. ( 5.1 ) Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of brexpiprazole tablets have not been established in pediatric patients with MDD. ( 5.2 , 8.4 )